Loading
A phase 2 trial of Glecirasib in pancreatic ductal adenocarcinoma, run by Allist Pharmaceuticals, Inc., now recruiting.
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation. is a phase 2 interventional study registered as NCT06008288 by Allist Pharmaceuticals, Inc., with 88 participants planned, started 2023-10-27 and due to reach its primary completion in 2026-12-31. Interventions recorded: JAB-21822.
Shares Shanghai Allist Pharmaceuticals, Glecirasib, KRAS & RAS inhibitors, Small-molecule kinase inhibitors and the tag pipeline.
Shares KRAS G12C-mutant pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.
Shares Shanghai Allist Pharmaceuticals, Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic pancreatic ductal adenocarcinoma, Pancreatic ductal adenocarcinoma and the tag pipeline.